Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.48M | 39.21M | 43.73M | 44.71M | 58.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.48M | 39.21M | 43.73M | 44.71M | 58.89M |
| Cost of Revenue | 334.48M | 316.57M | 304.55M | 290.87M | 271.68M |
| Gross Profit | -283.00M | -277.36M | -260.82M | -246.16M | -212.80M |
| SG&A Expenses | 72.27M | 68.19M | 67.58M | 65.70M | 65.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 406.75M | 384.76M | 372.14M | 356.57M | 337.12M |
| Operating Income | -355.27M | -345.55M | -328.40M | -311.86M | -278.23M |
| Income Before Tax | -315.00M | -311.35M | -295.12M | -275.43M | -240.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -315.00 | -311.35 | -295.12 | -275.43 | -240.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -315.00M | -311.35M | -295.12M | -275.43M | -240.88M |
| EBIT | -355.27M | -345.55M | -328.40M | -311.86M | -278.23M |
| EBITDA | -348.59M | -338.83M | -321.54M | -305.06M | -271.67M |
| EPS Basic | -3.57 | -3.68 | -3.60 | -3.48 | -3.10 |
| Normalized Basic EPS | -2.20 | -2.27 | -2.22 | -2.17 | -1.94 |
| EPS Diluted | -3.57 | -3.68 | -3.60 | -3.48 | -3.10 |
| Normalized Diluted EPS | -2.20 | -2.27 | -2.22 | -2.17 | -1.94 |
| Average Basic Shares Outstanding | 355.20M | 337.81M | 327.88M | 316.71M | 309.32M |
| Average Diluted Shares Outstanding | 355.20M | 337.81M | 327.88M | 316.71M | 309.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |